Who Paid My Doc
Fetroja
Drug Infections and Infectious Diseases
NDC 59630-266-10
General payments
$3,677,223
Research payments
$3,335,118
Through program year 2025, $3,677,223 in general payments and $3,335,118 in research payments were reported against Fetroja (Infections and Infectious Diseases).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
14 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $671,548 | 4,923 |
| 2025 | Research | $306,486 | 36 |
| 2024 | General | $946,587 | 5,600 |
| 2024 | Research | $330,958 | 29 |
| 2023 | General | $497,985 | 4,687 |
| 2023 | Research | $240,573 | 8 |
| 2022 | General | $584,562 | 4,195 |
| 2022 | Research | $802,625 | 39 |
| 2021 | General | $258,663 | 2,051 |
| 2021 | Research | $230,091 | 19 |
| 2020 | General | $260,521 | 469 |
| 2020 | Research | $635,685 | 44 |
| 2019 | General | $457,355 | 443 |
| 2019 | Research | $788,700 | 115 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 71 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 46 states; each share is of general payments naming this product in 2025 where a state was reported.
Prescribed to Medicare patients
Part D · data year 2024Part D claims
764
Drug cost
$1,607,724
Prescribers
37
| Part D drug | Name match | Relative to the largest | Prescribers | Claims | Drug cost |
|---|---|---|---|---|---|
| Fetroja Cefiderocol Sulfate Tosylate | Same name | 37 | 764 | $1,607,724 |
Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.
Largest prescribers
First 5 of 37 by claims · 2024Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.
| Prescriber | Specialty | State | Claims | Drug cost | Related payments |
|---|---|---|---|---|---|
| Joseph Durandis | Family Practice | FL | 81 | $63,264 | None on record |
| Khalid Noori | Internal Medicine | NY | 70 | $102,347 | None on record |
| Sai Chandran | Internal Medicine | AZ | 37 | $171,581 | None on record |
| Sujata Sharma | Family Practice | TX | 37 | $53,332 | None on record |
| Suhasini Gudipati | Internal Medicine | MI | 36 | $46,928 | None on record |
"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.
See more in the dashboard: 25 with a free account, all 37 with PatronRecords
22,368 general · 290 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.